A. Christie

发表

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Selective inhibition of BET bromodomains

William B. Smith, S. Knapp, M. McKeown, 2010, Nature.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Steven B. Neuhauser, Yvonne A. Evrard, Matthew H. Brush, 2017, Cancer research.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction

Yonghong Xiao, Andrew L. Kung, Steven P. Gygi, 2011 .

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

A. Letai, S. Sallan, M. Harris, 2015, Cancer cell.

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

A. Letai, A. Look, A. Kentsis, 2016, Leukemia.

Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance

B. Ebert, G. Adelmant, J. Marto, 2014, Nature Medicine.

Inhibition of USP10 induces degradation of oncogenic FLT3.

A. Letai, K. Anderson, N. Gray, 2017, Nature chemical biology.

A Unique B-cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B-cell Lymphomas

Bernstein, Shawn M. Gillespie, J. Aster, 2017 .

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

R. Bronson, A. Christie, A. Kung, 2012, Leukemia.

Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models

C. Vanderburg, A. Beheshti, J. McDonald, 2019, Scientific Reports.

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

Kristen L. Jones, Kristen L Jones, A. Letai, 2019, The Journal of clinical investigation.

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

J. Griffin, A. Christie, A. Kung, 2012, Genes & cancer.

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

K. Ross, K. Stegmaier, N. Gray, 2014, Oncotarget.

Smac mimetics: implications for enhancement of targeted therapies in leukemia

D. Porter, L. Zawel, A. Christie, 2010, Leukemia.

Differentiation of NUT midline carcinoma by epigenomic reprogramming.

J. Aster, J. Bradner, S. Sallan, 2011, Cancer research.

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti–Prostate Cancer Activity

P. Kantoff, Xiaodong Wang, A. Christie, 2015, Clinical Cancer Research.

Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML

S. Armstrong, R. Bronson, Christopher C. Ebmeier, 2015, Nature.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

The requirement for cyclin D function in tumor maintenance.

A. Look, S. Signoretti, A. Christie, 2012, Cancer cell.

A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.

Shawn M. Gillespie, J. Aster, B. Bernstein, 2017, Cell reports.

High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.

M. Rivera, M. Fleming, B. Crompton, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology High-Throughput Tyrosine Kinase Activity Pro fi ling Identi fi es FAK as a Candidate Therapeutic Target in Ewing Sarcoma

M. Rivera, B. Crompton, A. Thorner, 2013 .

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Andrew L. Kung, Jonathan D. Licht, Alex Kentsis, 2012, Nature Medicine.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Joshua M. Dempster, Henry W. Long, B. Haas, 2018, Nature Communications.

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.

G. Ciriello, V. Zoete, O. Michielin, 2018, Blood.

Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition

D. Erdmann, M. McKeown, J. Bradner, 2012 .

KPT‐330 inhibitor of CRM1 (XPO1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid leukaemia

A. Letai, A. Kentsis, S. Rodig, 2013, British journal of haematology.

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

S. Rodig, A. Christodoulou, A. Christie, 2016, Blood.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Joshua M. Dempster, Henry W. Long, E. D. Jacobsen, 2018, Nature Communications.

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

N. Munshi, P. Richardson, A. Christie, 2014, Blood.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

N. Gray, C. Mitsiades, J. Griffin, 2014, Leukemia.

SCFFbw7 Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction

S. Gygi, Yonghong Xiao, R. DePinho, 2010, Nature.

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

A T Look, M R Mansour, A. Look, 2012, Leukemia.

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.

S. Monti, R. Gascoyne, G. Pinkus, 2016, Blood.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

N. Gray, Qingsong Liu, J. Griffin, 2015, Blood.

Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.

Kristen L Jones, J. Aster, S. Prakadan, 2019, Cancer discovery.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

N. Gray, Qingsong Liu, W. Hur, 2012, Leukemia.

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

W. Hahn, M. Rivera, K. Ligon, 2022, bioRxiv.

Smac mimetics: implications for enhancement of targeted therapies in leukemia

D. Porter, L. Zawel, A. Christie, 2011, Leukemia.

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

A. Letai, L. Drew, A. Christie, 2019, Blood.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

K. Stegmaier, S. Lazo, J. Griffin, 2017, Oncotarget.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

K. Stegmaier, S. Lazo, J. Griffin, 2017, Oncotarget.

Reprogramming Differentiation of NUT Midline Carcinoma by Epigenomic

J. Aster, J. Bradner, S. Sallan, 2011 .

Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma

A. Letai, A. Christie, M. Davids, 2017 .

Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance

B. Ebert, G. Adelmant, J. Marto, 2014, Nature Medicine.

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

G. Adelmant, J. Marto, Kutlu G. Elpek, 2014 .

Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin

J. Boehm, B. Crompton, K. Stegmaier, 2024, Communications Biology.

Differentiation of NUT midline carcinoma by epigenomic reprogramming.

J. Aster, J. Bradner, S. Sallan, 2011, Cancer research.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

N. Gray, Qingsong Liu, J. Griffin, 2015, Blood.